Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 1, 2018

View Archived Issues

Fusion of neoplastic cells with macrophages confers metastatic growth advantages and poor prognosis

Bispecific-anchored cytotoxicity activator antibody induces ovarian cancer cell death

Ability to analyze old samples leads to new ovarian cancer biomarker

Atlantic Healthcare reports phase I data on oral alicaforsen for Crohn's disease

Sanwa Kagaku Kenkyusho obtains approval for Metoana in Japan

FDA gives favorable response to pre-IND meeting package for phase II study of CSTD002-NK

NO signals quorum for macrophages

Combination antibodies suppress HIV and resistance

Exhausted T cells play role in fibrosis

Cell cycle kinase affects platelet cytoskeleton

Korea Research Institute of Chemical Technology and collaborators patent GPR119 agonists

Sunshine Lake Pharma describes new SLC22A12 and xanthine oxidase inhibitors

Lytix Biopharma initiates recruitment in the sarcoma study of LTX-315

New PRMT5 inhibitors discovered at Prelude Therapeutics

FDA approves IND application to initiate clinical testing of TT-00420 in TNBC

Eli Lilly presents nuclear receptor ROR-gammaT inverse agonists

Achillion Pharmaceuticals identifies complement factor D inhibitors

BIT225-009 phase II study demonstrates significant immunological benefits in HIV-infected patients

FDA approves Fycompa for partial-onset seizures in pediatric patients

Promising outcome of IDMC interim review for phase II study of F-351 for liver fibrosis

FDA approves Libtayo for cutaneous squamous cell carcinoma

Innovent cleared to conduct clinical trials of IBI-188

FDA grants accelerated approval to Arikayce for MAC lung disease

AvroBio updates gene therapy programs in Gaucher's disease and Fabry disease

VEGF-D, MMP-2 and MMP-7 biomarkers in lymphangioleiomyomatosis and tuberous sclerosis complex

CaSR found as a novel therapeutic target for pulmonary fibrosis

NEAT1 found as new therapeutic target for occlusive vascular diseases

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...